Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis

Kai-Helge Schmidt¹, Katrin Milger², Christine Pausch³, Doerte Huscher⁴, David Pittrow^{3

5}, Ekkehard Grünig⁶, Gerd Staehler⁷, Henning Gall^{8

9}, Oliver Distler¹⁰, Dirk Skowasch¹¹, Michael Halank¹², Heinrike Wilkens¹³, Matthias Held¹⁴, Hans Klose¹⁵, Marius M Hoeper^{16

17}

Affiliations

¹ Department of Cardiology and Center of Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Mainz, Germany.
² Department of Medicine V, University Hospital, LMU Munich, Comprehensive Pneumology Center Munich (CPC-M), member of the German Center for Lung Research (DZL), Munich, Germany.
³ GWT-TUD GmbH, Innovation Center Real-World Evidence, Dresden, Germany.
⁴ Institute of Biometry and Clinical Epidemiology, and Berlin Institute of Health, Charité-Universitätsmedizin, Berlin, Germany.
⁵ Institute for Clinical Pharmacology, Medical Faculty, Technical University, Dresden, Germany.
⁶ Center for Pulmonary Hypertension, Thoraxklinik at Heidelberg University Hospital, Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.
⁷ Fachklinik Löwenstein, Löwenstein, Germany.
⁸ Department of Internal Medicine, Justus-Liebig-University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany.
⁹ German Center of Lung Research (DZL), Germany.
¹⁰ Department of Rheumatology, University Hospital, Zurich, Switzerland.
¹¹ Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik II, Innere Medizin - Kardiologie/Pneumologie, Bonn, Germany.
¹² Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany.
¹³ Klinik für Innere Medizin V, Pneumologie, Universitätsklinikum des Saarlandes, Homburg, Germany.
¹⁴ Department of Internal Medicine, Respiratory Medicine and Ventilatory Support, Medical Mission Hospital, Central Clinic Würzburg, Würzburg, Germany.
¹⁵ Department of Respiratory Medicine, Eppendorf University Hospital, Hamburg, Germany.
¹⁶ German Center of Lung Research (DZL), Germany hoeper.marius@mh-hannover.de.
¹⁷ Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany.

PMID: 37105586
PMCID: PMC10133582
DOI: 10.1183/13993003.02440-2022

Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis

Kai-Helge Schmidt et al. Eur Respir J. 2023.

. 2023 Apr 27;61(4):2202440.

doi: 10.1183/13993003.02440-2022. Print 2023 Apr.

Authors

Affiliations

¹ Department of Cardiology and Center of Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Mainz, Germany.
² Department of Medicine V, University Hospital, LMU Munich, Comprehensive Pneumology Center Munich (CPC-M), member of the German Center for Lung Research (DZL), Munich, Germany.
³ GWT-TUD GmbH, Innovation Center Real-World Evidence, Dresden, Germany.
⁴ Institute of Biometry and Clinical Epidemiology, and Berlin Institute of Health, Charité-Universitätsmedizin, Berlin, Germany.
⁵ Institute for Clinical Pharmacology, Medical Faculty, Technical University, Dresden, Germany.
⁶ Center for Pulmonary Hypertension, Thoraxklinik at Heidelberg University Hospital, Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.
⁷ Fachklinik Löwenstein, Löwenstein, Germany.
⁸ Department of Internal Medicine, Justus-Liebig-University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany.
⁹ German Center of Lung Research (DZL), Germany.
¹⁰ Department of Rheumatology, University Hospital, Zurich, Switzerland.
¹¹ Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik II, Innere Medizin - Kardiologie/Pneumologie, Bonn, Germany.
¹² Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany.
¹³ Klinik für Innere Medizin V, Pneumologie, Universitätsklinikum des Saarlandes, Homburg, Germany.
¹⁴ Department of Internal Medicine, Respiratory Medicine and Ventilatory Support, Medical Mission Hospital, Central Clinic Würzburg, Würzburg, Germany.
¹⁵ Department of Respiratory Medicine, Eppendorf University Hospital, Hamburg, Germany.
¹⁶ German Center of Lung Research (DZL), Germany hoeper.marius@mh-hannover.de.
¹⁷ Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany.

PMID: 37105586
PMCID: PMC10133582
DOI: 10.1183/13993003.02440-2022

Abstract

In patients with pulmonary hypertension, the mortality rate associated with COVID-19 has declined sharply with the emergence of the Omicron variants https://bit.ly/42OMsfj

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: K-H. Schmidt has received fees for lectures and educational events from Abbott, Janssen and MSD. K. Milger has received fees from Actelion, AstraZeneca, GSK, Janssen, MSD, Novartis and Sanofi-Avensis. C. Pausch has no disclosures. D. Huscher has received travel compensation from Shire. D. Pittrow has received fees for consultations from Actelion, Amgen, Aspen, Bayer, Biogen, Boehringer Ingelheim, Daiichi Sankyo, MSD, Novartis, Sanofi-Genzyme, Takeda, Viatris and Zambon. E. Grünig has received fees for lectures and/or consultations from Actelion, Bayer, Ferrer, GSK, Janssen, MSD and Orpha Care. G. Staehler has received honoraria for lectures and/or consultancy for Actelion, Bayer, GSK, Novartis and Pfizer. H. Gall reports personal fees from Actelion, AstraZeneca, Bayer, BMS, GossamerBio, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer and United Therapeutics. O. Distler has/had consultancy relationship and/or has received research funding from 4 D Science, Actelion, Active Biotec, Bayer, Biogen Idec, Boehringer Ingelheim Pharma, BMS, ChemoAb, EpiPharm, Ergonex, espeRare foundation, GSK, Genentech/Roche, Inventiva, Janssen, Lilly, medac, MedImmune, Mitsubishi Tanabe, Pharmacyclics, Pfizer, Sanofi, Serodapharm and Sinoxa in the area of potential treatments of scleroderma and its complications, including PAH; and in addition, has a patent mir-29 for the treatment of systemic sclerosis licensed. D. Skowasch received fees for lectures and/or consulting and/or research support to institution from Actelion, Bayer, GSK, Janssen, MSD and Pfizer. M. Halank has received speaker fees and honoraria for consultations from Acceleron, Actelion, AstraZeneca, BerlinChemie, GSK, Janssen and MSD. H. Wilkens received fees for lectures and/or consultations from Actelion, Bayer, Biotest, Boehringer, GSK, Janssen, MSD, Pfizer and Roche. M. Held has received speaker fees and honoraria for consultations from Actelion, Bayer, Boehringer Ingelheim Pharma, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer, Nycomed, Roche and Servier. H. Klose has received speaker fees and honoraria for consultations from Actelion, Bayer, GSK, Janssen, MSD, Novartis, Pfizer and United Therapeutics. M.M. Hoeper has received fees for lectures and/or consultations from Acceleron, Actelion, AOP Health, Bayer, Ferrer, GSK, Janssen, MSD and Pfizer.

References

1. Belge C, Quarck R, Godinas L, et al. . COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey. ERJ Open Res 2020; 6: 00520-2020. doi:10.1183/23120541.00520-2020 - DOI - PMC - PubMed
1. Sulica R, Cefali F, Motschwiller C, et al. . COVID-19 in pulmonary artery hypertension (PAH) patients: observations from a large PAH center in New York City. Diagnostics (Basel) 2021; 11: 128. doi:10.3390/diagnostics11010128 - DOI - PMC - PubMed
1. Mamzer A, Waligora M, Kopec G, et al. . Impact of the COVID-19 pandemic on pulmonary hypertension patients: insights from the BNP-PL National database. Int J Environ Res Public Health 2022; 19: 8423. doi:10.3390/ijerph19148423 - DOI - PMC - PubMed
1. Farmakis IT, Karyofyllis P, Frantzeskaki F, et al. . Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: data from the Hellenic pulmOnary hyPertension rEgistry (HOPE). Hellenic J Cardiol 2022; 64: 93–96. doi:10.1016/j.hjc.2021.10.002 - DOI - PMC - PubMed
1. Montani D, Certain MC, Weatherald J, et al. . COVID-19 in patients with pulmonary hypertension: a national prospective cohort study. Am J Respir Crit Care Med 2022; 206: 573–583. doi:10.1164/rccm.202112-2761OC - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis

Affiliations

Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous